GDF2 and hereditary hemorrhagic telangiectasia: Ruiz et al. more recently reported that in the same neonatal mouse model of HHT (BMP9/BMP10 immunosupressed mouse), the combination of sirolimus, an mTOR inhibitor, and nintedanib, an inhibitor of the tyrosine kinase receptor, exhibited a synergistic effect, completely inhibiting and even reversing retinal AVMs.